Kremer JM, et al. - Researchers assessed if tocilizumab (TCZ) monotherapy is noninferior to treatment with TCZ plus methotrexate (MTX) for sustaining clinical response in patients with rheumatoid arthritis (RA) in whom low disease activity is attained with TCZ plus MTX. As per data, MTX could be discontinued by patients with RA receiving TCZ plus MTX who achieve low disease activity without significant worsening of disease activity during the 16 weeks following MTX discontinuation. Between the randomized treatment groups, safety events were broadly similar. Infection was the most common serious adverse event, which occurred in 2.1% of patients in the TCZ monotherapy group and 2.2% of patients receiving TCZ plus MTX.